Opinion statement
The main goal in the treatment of Duchenne muscular dystrophy (DMD) is to maintain ambulation for as long as possible and to anticipate and manage the associated complications, such as joint contractures, scoliosis, cardiomyopathy, respiratory insufficiency, and weight gain. Cognitive and behavioral symptoms occur in about one third of patients, and it is important to recognize and manage them promptly, developing an individualized plan at school and at home to maximize the patient’s cognitive abilities. In the late phase of the disease, palliative care is of paramount importance.
Corticosteroid therapy (prednisone and deflazacort) is the only effective pharmacologic treatment for DMD. Daily prednisone treatment increases muscle strength and function, improves pulmonary function, and significantly slows the progression of weakness. Deflazacort has a similar effect on muscle strength, but it is not available in the United States. Treatment with corticosteroid should be offered to all patients with DMD, but the beneficial effects and potential adverse effects should be fully discussed before treatment begins. The optimal dose of prednisone is 0.75 mg/kg per day, up to a maximum of 40 mg/d. If adverse effects occur, a decrease in dosage is appropriate. Monitoring of muscle function and adverse effects by a neurologist or neuromuscular specialist is strongly recommended.
Physical and occupational therapists should be involved early in the treatment of patients with DMD to develop a program that includes heel cord stretching and exercise. In the later phases, these therapists can recommend adaptive equipment and maximize independence.
Orthopedic consultation is important in monitoring and managing scoliosis and joint contractures in the nonambulatory phase of the disease.
Pulmonary evaluation for ventilatory care is important; pulmonary consultation is essential when vital capacity declines. The use of assistive cough devices, nasal bilevel positive airway pressure, and tracheostomy must be discussed with patients and their families.
For all patients with DMD, particularly those receiving prednisone, consultation with a dietitian is very helpful to control weight and maintain a healthy diet.
Similar content being viewed by others
References and Recommended Reading
Mendell JR, Moxley RT, Griggs RC, et al.: Randomized, double-blind six-month trial of prednisone in Duchenne’s muscular dystrophy. N Engl J Med 1989, 320:1592–1597.
Moxley RT 3rd, Ashwal S, Pandya S, et al.: Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2005, 64:13–20.
Manzur AY, Kuntzer T, Pike M, Swan A: Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Rev 2004, 2:1–55.
Kinali M, Main M, Eliahoo J, et al.: Predictive factors for development of scoliosis in Duchenne muscular dystrophy. Eur J Paediatr Neurol 2007, 11:160–166.
King WM, Ruttencutter R, Nagaraja HN, et al.: Orthopedic outcomes of long-term daily corticosteroids treatment in Duchenne muscular dystrophy. Neurology 2007, 68:1607–1613.
Leitch KK, Raza N, Biggar D, et al.: Should foot surgery be performed for children with Duchenne muscular dystrophy? J Pediatr Orthop 2005, 25:95–97.
Bakker JPJ, de Groot IJM, Beckerman H, et al.: The effects of knee-ankle-foot orthoses in the treatment of Duchenne muscular dystrophy: review of the literature. Clin Rehabil 2000, 14:343–359.
Birnkrant DJ, Panitch HB, Benditt JO, et al.: American College of Chest Physicians consensus statement on the respiratory and related management of patients with Duchenne muscular dystrophy undergoing anesthesia or sedation. Chest 2007, 132:1977–1986.
Passaquin AC, Renard M, Kay L, et al.: Creatine supplementation reduces skeletal muscle degeneration and enhances mitochondrial function in mdx mice. Neuromuscul Disord 2002, 12:174–182.
Tarnopolsky MA, Mahoney DJ, Vajsar J, et al.: Creatine monohydrate enhances strength and body composition in Duchenne muscular dystrophy. Neurology 2004, 62:1771–1777.
Escolar DM, Buyse G, Henricson E, et al.: CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy. Ann Neurol 2005, 58:151–155.
Escolar DM: Open label pilot trial of coenzyme Q 10 in steroid treated Duchenne muscular dystrophy [abstract]. Ann Neurol 2006, 60(Suppl 3):S132.
Duboc D, Meune C, Pierre B, et al.: Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years’ follow-up. Am Heart J 2007, 154:596–602.
Cohn RD, van Erp C, Habashi JP, et al.: Angiotensin II type 1 receptor blockade attenuates TGF-β-induced failure of muscle regeneration in multiple myopathic states. Nat Med 2007, 13:204–210.
Welch EM, Barton ER, Zhuo J, et al.: PTC 124 targets genetic disorders caused by nonsense mutations. Nature 2007, 447:87–91.
Hirawat S, Welch EM, Elfring GL, et al.: Safety, tolerability, and pharmacokinetics of PTC 124, a nonaminoglycoside nonsense mutation suppressor, following single and multiple-dose administration to healthy male and female adult volunteers. J Clin Pharmacol 2007, 47:430–444.
Wagner KR, McPherron AC, Winik N, Lee SJ: Loss of myostatin attenuates severity of muscular dystrophy in mdx mouse. Ann Neurol 2002, 52:832–836.
Bogdanovich S, Krag TOB, Barton ER, et al.: Functional improvement of dystrophic muscle by myostatin blockade. Nature 2002, 420:418–421.
Gregorevic P, Blankinship MJ, Allen JM, et al.: Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med 2004, 10:828–834.
Rodino-Klapac LR, Chicoine LG, Kaspar BK, Mendell JR: Gene therapy for Duchenne muscular dystrophy. Arch Neurol 2007, 64:1236–1241.
Sampaolesi M, Blot S, D’Antona G, et al.: Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. Nature 2006, 444:574–579.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ciafaloni, E., Moxley, R.T. Treatment options for Duchenne muscular dystrophy. Curr Treat Options Neurol 10, 86–93 (2008). https://doi.org/10.1007/s11940-008-0010-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11940-008-0010-4